Ramucirumab plus erlotinib combination is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.1 In this exclusive video, Dr. Maximillian Hochmair presents data from the RELAY trial (ramucirumab + erlotinib) in EGFR mutated advanced NSCLC.
Reference 1. Cyramza Abridged Pack Insert, May 2021 (India).
China Reports First Commercial Brain-Computer Interface Implant for Spinal Cord Injury
Anatomy & Physiology
1m ago
0
Rare Triple Procedure Addresses Breast Cancer and Silent Cardiac Disease in One Operation
Cardiology
1m ago
0
What is Your Diagnosis for This Patient with a Painless Lesion on the Tongue?
Oral and Maxillofacial Surgery
3h ago
89
India Adds Nearly 10,000 MBBS Seats for 2026 to 2027 Academic Session
Allergy & Immunology
5h ago
112
Andhra Pradesh Reports 12 COVID-19 Infections and Four Deaths Between June 26 and July 16
Anesthesiology
10h ago
173
1
Mumbai Reports Nearly Threefold Rise in H1N1 Cases During First Half of 2026
Anesthesiology
1d ago
576
3